Dietary restrictions and drug interactions with monoamine oxidase inhibitors: The state of the art

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 8, 2007, Pages 42-46

  Rapaport, Mark Hyman ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; COCAINE; DEXTROMETHORPHAN; DIAZEPAM; EPHEDRINE; FENTANYL; FENTORA; FLUOXETINE; GLUTAMATE SODIUM; GUANETHIDINE; ISOCARBOXAZID; LABETALOL; METHYLDOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MORPHINE SULFATE; NICARDIPINE; PETHIDINE; PHENELZINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; RESERPINE; SELEGILINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; TYRAMINE; UNCLASSIFIED DRUG;

AVOCADO; BEER; BLOOD PRESSURE; BRAIN HEMORRHAGE; CACAO; CHEESE; CONVULSION; DIET RESTRICTION; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG MECHANISM; FERMENTED PRODUCT; FLUSHING; FOOD COMPOSITION; FOOD DRUG INTERACTION; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MAJOR DEPRESSION; MUSCLE RIGIDITY; NAUSEA; NECK PAIN; NOSE DISEASE; PRIORITY JOURNAL; RED WINE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SOYBEAN; SWEATING; TACHYCARDIA; THORAX PAIN; VICIA FABA; VOMITING; YEAST;

DEPRESSIVE DISORDER; DIET; FOOD-DRUG INTERACTIONS; HUMANS; HYPERTENSION; MONOAMINE OXIDASE INHIBITORS; TYRAMINE;

EID: 34547530313     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Shulman KI, Walker SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:397-402
2. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963;38:849-850
3. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet 1963;54:733-734
4. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-365
5. Robinson DS. Monomamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002;36:124-138
6. Horwitz D, Lovenberg W, Engleman K, et al. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA 1964;188:1108-1110
7. McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry 1982;43:178-181
8. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibits: a re-examination. Can J Psychiatry 1984;29:707-711
9. Folks D. Monoamine oxidase inhibitors: reappraisal of dietary considerations. J Clin Psychopharmacol 1983;3:249-252
10. Blackwell B, Marley E, Mabbitt LA. Effects of yeast extract after monoamine-oxidase inhibition. Lancet 1965;240:940-943
11. Hodge JV, Nye ER, Emerson GW. Monoamine-oxidase inhibitors, broad beans, and hypertension. Lancet 1964;13:1108
12. Boulton AA, Cookson B, Paulton R. Hypertensive crisis in a patient on MAOI antidepressants following a meal of beef liver. Can Med Assoc J 1970;102:1394-1395
13. Hedberg DL, Gordon MW, Glueck BC. Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am J Psychiatry 1966;122:933-937
14. Generali JA, Hogan LC, McFarlane M, et al. Hypertensive crisis resulting from avocados and a MAO inhibitor. Drug Intell Clin Pharm 1981;15:904-906
15. Amsterdam JD, Chopra M. Monoamine oxidase inhibitors revisited. Psychiatr Ann 2001;31:361-370
16. Fiedorowicz J, Swartz K. The role of monoamine oxidase inhibitors in psychiatric practice. J Psychiatr Pract 2004;10:239-248
17. Wecker L, Pacheco MA. A neurochemical perspective on monoamine oxidase inhibitors. Psychiatr Ann 2001;31:354-360
18. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-214
19. Marley E, Blackwell B. Interactions of monoamine oxidase inhibitors, amines and foodstuffs. Adv Pharmacol Chemother 1970;8:185-239
20. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-365
21. Bieck PR, Antonin K. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988;8:237-245
22. Blackwell B, Mabbitt LA. Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet 1965;62:938-940
23. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996;57:99-104
24. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizza and soy products. J Clin Psychiatry 1999;60:191-193
25. Sweet RA, Brown EJ, Heimberg RG, et al. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry 1995;56:196-201
26. McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry 1982;43:178-181
27. Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520-526
28. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713
29. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104
30. Holschneider DP, Shih JC. Monoamine oxidase: basic and clinical perspectives. In: Psychopharmacology: The Fourth Generation of Progress. Nashville, TN: American College of Neuropsychopharmacology; 2000
31. Mills KC. Serotonin syndrome. Am Fam Physician 1995;52:1475-1482
32. Skop BP, Finkelstein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994;12:642-644
33. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-533
34. Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995;56(suppl 2):38-48
35. Boyer EW, Shannon M. The serotonin syndrome. New Engl J Med 2005;352:1112-1120
36. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992;43(suppl 2):3-9
37. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994;24:983-985
38. Nolan S, Scoggin AJ. Serotonin syndrome: recognition and management. US Pharm 1998;23:87-94
39. Aggarwal M, Kahn IA. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin 2006;24:135-146
40. Jenkins LC, Graves HB. Potential hazards of psychoactive drugs in association with anaesthesia. Can Anaesth Soc J 1965;12:121-128
41. Cockhill LA, Remick RA. Blood pressure effects of monoamine oxidase inhibitors - the highs and lows. Can J Psychiatry 1987;32:803-808